SELLAS Life Sciences (SLS) Total Liabilities (2010 - 2026)

SELLAS Life Sciences (SLS) has 17 years of Total Liabilities data on file, last reported at $6.8 million in Q1 2026.

• On a quarterly basis, Total Liabilities fell 6.0% year-over-year to $6.8 million in Q1 2026; TTM through Mar 2026 was $6.8 million, a 6.0% decrease from a year earlier, with the FY2025 full-year figure at $7.5 million, down 25.01% from the prior year.
• Total Liabilities for Q1 2026 stood at $6.8 million, down from $7.5 million in the prior quarter.
• Over the last five years, Total Liabilities for SLS reached as high as $17.4 million in Q1 2022 and fell as low as $5.9 million in Q3 2025.
• Historically, Total Liabilities has averaged $11.6 million across 5 years, with a median of $12.2 million in 2024.
• Across the five-year window, Total Liabilities soared 171.46% in 2022 and plunged 51.21% in 2025, its largest moves.
• Year by year, Total Liabilities stood at $16.1 million in 2022, then fell by 11.79% to $14.2 million in 2023, then retreated by 29.79% to $10.0 million in 2024, then decreased by 25.01% to $7.5 million in 2025, then retreated by 9.49% to $6.8 million in 2026.
• Per Business Quant data, the three most recent Total Liabilities figures were $6.8 million in Q1 2026, $7.5 million in Q4 2025, and $5.9 million in Q3 2025.